MARKET

LUMO

LUMO

Lumos Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.44
-0.53
-3.54%
After Hours: 14.00 -0.44 -3.05% 19:34 03/02 EST
OPEN
14.68
PREV CLOSE
14.97
HIGH
15.11
LOW
14.28
VOLUME
19.78K
TURNOVER
--
52 WEEK HIGH
36.72
52 WEEK LOW
6.74
MARKET CAP
119.81M
P/E (TTM)
-5.6093
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Lumos Pharma to Present Poster Demonstrating Greater GH Response to LUM-201 than to Standard GH Secretagogues in PGHD at the Endocrine Society (ENDO) 2021 Annual Meeting
GlobeNewswire · 11h ago
Will Lumos Pharma (LUMO) Report Negative Earnings Next Week? What You Should Know
Zacks.com · 15h ago
Lumos Pharma to Report Full Year 2020 Financial Results and Host Conference Call on March 9, 2021
Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its full year 2020 financial results after market close on Tuesday, March 9, 2021. The company will host ...
GlobeNewswire · 02/22 21:15
Press Release: Lumos Pharma Announces Changes to its Board of Directors
Dow Jones · 02/16 21:01
Lumos Pharma Issued U.S. Patent 10,898,472 'Detecting and treating growth hormone deficiency'
View patent here
Benzinga · 01/26 12:16
SYN, TRXC, JAGX and BNGO among midday movers
Gainers: Synthetic Biologics (SYN) +141%.Helius Medical Technologies (HSDT) +91%.The Peck Company (PECK) +79%.Atomera (ATOM) +50%.Check-Cap (CHEK) +49%.Naked Brand Group (NAKD) +42%.The9 (NCTY) +37%.Gritstone Oncology (GRTS) +36%.Boston Private Financial (BPFH) +31%.Jaguar Health (JAGX) +20%.Losers: Mersana
Seekingalpha · 01/05 17:42
The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 29)
Benzinga · 12/30/2020 13:08
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28)
Benzinga · 12/29/2020 13:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LUMO. Analyze the recent business situations of Lumos Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LUMO stock price target is 33.00 with a high estimate of 51.00 and a low estimate of 22.00.
EPS
Institutional Holdings
Institutions: 120
Institutional Holdings: 6.04M
% Owned: 72.77%
Shares Outstanding: 8.30M
TypeInstitutionsShares
Increased
7
59.71K
New
17
93.94K
Decreased
12
19.09K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/President/Chief Executive Officer/Director
Richard Hawkins
Chief Financial Officer
Carl Langren
Chief Executive Officer
Brad Powers
Chief Operating Officer/Chief Scientific Officer
John McKew
Senior Vice President - Finance/Chief Accounting Officer/Controller
Lori Lawley
General Counsel
Bradley Powers
Other
Eugene Kennedy
Other
Aaron Schuchart
Lead Director/Independent Director
Thomas Raffin
Director
Joe McCracken
Director
An van Es-Johansson
Director
Nicholas Vahanian
Independent Director
Emmett Cunningham
Independent Director
Chad Johnson
Independent Director
Kevin Lalande
Independent Director
Joseph McCracken
Independent Director
Lota Zoth
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About LUMO
Lumos Pharma, Inc., formerly NewLink Genetics Corporation, is a clinical stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for rare diseases. Its lead product candidate is LUM-201, an oral growth hormone stimulating therapeutic, is in late stage clinical development for the treatment of Pediatric Growth Hormone Deficiency (PGHD). LUM-201 is an orally administered small molecule that promotes the secretion (secretagogue) of Growth Hormone (GH) from the pituitary gland. LUM-201 acts as an agonist of the GH Secretagogue Receptor to stimulate GH release. The Company’s pipeline features development programs in rare diseases associated with growth hormone deficiencies.

Webull offers kinds of Lumos Pharma Inc stock information, including NASDAQ:LUMO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LUMO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LUMO stock methods without spending real money on the virtual paper trading platform.